Avtor/Urednik		Glavan, G; Živin, M
Naslov		Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats
Tip		članek
Vir		Neuroscience
Vol. in št.		, št. 135
Leto izdaje		2005
Obseg		str. 545-54
Jezik		eng
Abstrakt		Synaptotagmins (Syts) constitute a multi-gene family of 15 putative membrane trafficking proteins. The expression of some of the Syts in the brain might be dopaminergically controlled and thus affected by dopamine depletion in Parkinson's disease. We used hemiparkinsonian rats to investigate the effects of chronic striatal dopamine depletion and the acute effects of antiparkinsonic drug L-DOPA or D1 agonist (±)-6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5tetrahydro-1H-3-benzazepine hydrobromide (SKF82958) on the levels of striatal Syt I, II, IV, VI, VII, X, XI mRNA isoforms. On the 6-hydroxydopamine (6-OHDA)-lesioned side we observed a nearly total loss of tyrosine hydroxylase (TH), synaptotagmin I, Syt IV, Syt VII and Syt XI mRNA levels in the substantia nigra compacta (SNc). In dopamine-depleted striatum we also found a significant down-regulation Syt II and up-regulation of Syt X mRNA levels that could not be reversed by the acute treatment either with L-DOPA or SKF82958. By contrast, these two drugs induced an increase of Syt IV and Syt VII mRNA levels. A time-course study revealed the highest levels of Syt IV and VII mRNAs to occur at two hours and 12 hours after the treatment with SKF82958, respectively. D1 antagonist (±)-7-chloro-8-hydroxy-3-methyl1-phenyl-2,3,4,5-tetrahydro-1H-3-b enzazepine hydrochloride (SCH23390) but not D2 antagonist haloperidol prevented the L-DOPA-driven increase of Syt IV and VII mRNAs. These results imply that synaptic plasticity in response to chronic dopamine depletion involves a complex pattern of changes in striatal Syt mRNA expression. (Abstract truncated at 2000 characters)
Deskriptorji		BEHAVIOR, ANIMAL CORPUS STRIATUM PARKINSON DISEASE GENE EXPRESSION GENE EXPRESSION REGULATION APOMORPHINE BRAIN DISEASE MODELS, ANIMAL DOPAMINE AGENTS DOPAMINE ANTAGONISTS DRUG INTERACTIONS LEVODOPA OXIDOPAMINE IN SITU HYBRIDIZATION RNA, MESSENGER RATS, WISTAR SUBSTANTIA NIGRA TIME FACTORS TYROSINE 3-MONOOXYGENASE